primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma
Phase 3 trial shows epcoritamab leads to improved progression-free survival and response rates in relapsed follicular lymphoma, suggesting a new standard of care.
Key Points
Epcoritamab plus rituximab and lenalidomide resulted in a significant overall response rate of 95.7%, greatly exceeding R2 alone at 81.0%.
The trial reported a substantial median improvement in progression-free survival with an HR of 0.21 for E+R2 versus R2.
Patients experienced manageable levels of neutropenia and infections, but only a small fraction suffered fatal adverse events with E+R2.
Epcoritamab’s efficacy in high-risk subgroups reinforces its potential as a new treatment benchmark in relapsed follicular lymphoma.